Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’
-
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeti
-
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at Americ
-
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
-
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
-
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
-
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
-
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
-
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
-
CWTI Provides Revised Update on Canada Postal Strike Delay Mailing of the Company's 2024 Annual General Meeting Materials
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leuke
-
EliteSignals Unveils Revolutionary Forex Trading Bot: EliteX
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
-
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
-
Caribbean Airlines Brings the Region Closer with New Service to Guadeloupe
-
Pennsylvania Skill, powered by Pace-O-Matic, Responds to Commonwealth Court Ruling in Favor of Skill Games
-
HII Christens Virginia-Class Attack Submarine Arkansas (SSN 800)
-
Admirals Group AS Announces a Sale of its Australian Subsidiary
-
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
-
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
-
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
-
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
-
Lonestar Transfer Reflects on 2024 Success Helping Over 25,000 Clients
-
Avance Gas Holding Ltd: Successfully completed the seventh VLGC delivery to BW LPG
-
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
-
Sallar Announces the Launch of Its Decentralized Computing Application
-
Fobi AI Provides Clarification On Total Holdings Previously Provided In The Company’s Information Circular
-
Fobi AI Provides Update on Current Cease Trade Order
-
Rugby Resources Ltd. Announces Results of its Annual General & Special Meeting
-
Sprott Physical Uranium Trust Announces Updated “At-the-Market” Equity Program
-
Sprott Physical Platinum and Palladium Trust Updates Its “At-the-Market” Equity Program
-
Sprott Physical Silver Trust Updates Its “At-the-Market” Equity Program
-
Sprott Physical Gold Trust Updates Its “At-the-Market” Equity Program
-
Sprott Physical Gold and Silver Trust Updates Its “At-the-Market” Equity Program
-
Mustang Energy Corp. Completes First Milestone of Option Agreement with Skyharbour Resources Ltd.
-
Voxtur Announces Amendments to Financial Statements and MD&A for Q3 Ended September 30, 2024
-
Voxtur Announces Amendments to Financial Statements and MD&A for Q3 Ended September 30, 2024
-
Brazilian Court Confirms Tenaris’s Obligation to Pay Indemnification in connection with its 2012 Acquisition of a Participation in Usiminas; the Decision is subject to Further Appeals
-
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
-
Tandy Leather Factory Announces Agreement to Sell Headquarters Facilities
-
Patagonia Gold Announces Increase to Loan Facility and Extension of Its Maturity Date
-
Zevra Therapeutics Announces Organizational Changes
-
Globalink Investment Inc. Announces Charter and Trust Agreement Amendments
-
Univest Securities, LLC Announces Closing of $9.5 Million Public Offering for its Client Algorhythm Holdings, Inc. (NASDAQ: RIME)
-
Rivalry Closes Third Tranche Of Non-Brokered Private Placement
-
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
-
Osisko Metals Acquires Additional Claims Near Gaspé Copper
-
Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)
